Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SpeechSwitch is a pioneering neurotechnology company dedicated to restoring communication for individuals with severe speech and physical impairments. Spun out of the laboratory of Dr. Edward Chang at the University of California, San Francisco (UCSF), the company develops high-performance brain-computer interfaces (BCI) that decode neural signals into synthesized speech. Their platform utilizes advanced machine learning to translate brain activity from the speech motor cortex directly into text or audible voice, bypassing damaged physiological pathways. SpeechSwitch aims to provide a life-changing solution for patients suffering from conditions such as ALS, stroke, and locked-in syndrome by enabling high-speed, naturalistic communication.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SpeechSwitch.